Clinical trials: Vascular
Coronary Artery Disease
ST Segment Detection Study
The purpose of ST Detect study is to evaluate whether naturally occurring spontaneous coronary events and exercise induced cardiac ischemia, give rise to detectable changes on intracardiac electrogram (EGM) signals in patients…
- Trial name
- ST Detect (NCT00930969)
- Testing
- ICD
- Where
- 25 sites in United States, Austria and 5 more
- Volunteers
- 175 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Multiple Myeloma
Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
This Phase I study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.
- Trial name
- NCT03994705
- Testing
- Descartes-11, Fludarabine, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Cartesian Therapeutics
Coronary Artery Disease, Coronary Restenosis
Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries
The process of re-narrowing of a coronary artery following a revascularization procedure such as angioplasty, begins at the time of the procedure.
- Trial name
- NCT00248066
- Testing
- RESTEN-MP
- Where
- 3 sites in Germany
- Volunteers
- 50 people
- Sponsor
- Sarepta Therapeutics, Inc.
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Multiple Myeloma in Relapse, Multiple Myeloma Refractory
Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial.
To Evaluate Safety and Efficacy of S103 for Treating Relapsed or Refractory Multiple Myeloma
- Trial name
- NCT07421856
- Testing
- Autologous BCMA-targeting CAR T cells
- Volunteers
- 24 people
- Sponsor
- Hebei Senlang Biotechnology Inc., Ltd.
Diabetes Mellitus
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus
The purpose of this study was to determine the efficacy of pioglitazone, once daily (QD), compared to glimepiride on atherosclerotic disease measured by intravascular ultrasound.
- Trial name
- PERISCOPE (NCT00225277)
- Testing
- Pioglitazone, Glimepiride
- Where
- 79 sites in United States, Argentina and 2 more
- Volunteers
- 547 people
- Sponsor
- Takeda
Peripheral Artery Disease
AcoArt Ⅱ/ BTK China: Drug-eluting Balloon for Below-The-Knee Angioplasty Evaluation in China
The purpose of this study is to determine whether DEB is more effective than common PTA balloon using under in long-term vessel patency and inhibiting restenosis in the infrapopliteal artery.
- Trial name
- NCT02137577
- Testing
- DEB catheter, common PTA balloon catheter
- Where
- 11 sites in China
- Volunteers
- 120 people
- Sponsor
- Acotec Scientific Co., Ltd
Hereditary Angioedema
NTLA-2002 in Adults With Hereditary Angioedema (HAE)
This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
- Trial name
- NTLA-2002 (NCT05120830)
- Testing
- Biological NTLA-2002, Normal Saline IV Administration
- Where
- 9 sites in Australia, France and 4 more
- Volunteers
- 37 people
- Sponsor
- Intellia Therapeutics
PAD - Peripheral Arterial Disease, PAD
Tack Optimized Balloon Angioplasty Post-Market Study
The objective of this study is to obtain outcomes following dissection repair with the Tack Endovascular System in a broad population of patients undergoing endovascular treatment of lesions within the superficial femoral…
- Conditions
- PAD - Peripheral Arterial Disease, PAD, Dissection, Arterial Dissection
- Trial name
- TOBA PMS (NCT05361967)
- Testing
- The Tack Endovascular System
- Where
- 10 sites in United States
- Volunteers
- 6 people
- Sponsor
- Spectranetics Corporation
Multiple Myeloma
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to evaluate how well JNJ-79635322 works when compared with an anti-B-cell maturation antigen (BCMA)xCD3 bispecific antibody.
- Trial name
- TRIlogy-4 (NCT07258511)
- Testing
- JNJ-79635322, Teclistamab
- Where
- 150 sites in United States, Australia and 13 more
- Volunteers
- 400 people
- Sponsor
- Janssen Research & Development, LLC
Intracranial Aneurysm
Endovascular Treatment of Wide Neck Intracranial Aneurysms With the LEO + Stent : The LEO + II Cohort Study
This is a prospective, multicenter, single-arm observational study to evaluate the efficacy and the morbi-mortality of LEO + in patients with wide neck intracranial aneurysms (fusiform, saccular or dissecting), ruptured or not…
- Trial name
- NCT03504436
- Testing
- LEO +
- Volunteers
- 176 people
- Sponsor
- Balt Extrusion
Retinal Vein Occlusion, Age Related Macular Degeneration
Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.
Ranibizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody fragment approved in Chile by the Instituto de Salud Pública for the treatment of diabetic macular edema (DME), retinal vein occlusion…
- Trial name
- NCT02140411
- Testing
- Ranibizumab Intravitreal injections
- Where
- Chile
- Volunteers
- 21 people
- Sponsor
- Novartis Pharmaceuticals
Cerebral Aneurysms
Contour Neurovascular System™ ContiNued Access Investigational Device EXempTion (IDE) Trial (NEXT Trial)
The goal of this clinical trial is to collect additional data to demonstrate if the Contour Neurovascular System (CNS) is a safe and effective treatment of wide-necked, saccular, intracranial aneurysms.
- Trial name
- NEXT (NCT06693011)
- Testing
- Contour Neurovascular System Treatment Attempt
- Where
- 9 sites in United States
- Volunteers
- 250 people
- Sponsor
- Cerus Endovascular, Inc.
Acute Ischemic Stroke
BXOS110 Injection in the Treatment of Acute Ischaemic Stroke
The purpose of this study was to evaluate the effectiveness of early administration of BXOS110 for injection in reducing overall disability in patients with acute ischaemic stroke.
- Trial name
- NCT06322394
- Testing
- high-dose BXOS110, low-dose BXOS110
- Where
- 24 sites in China
- Volunteers
- 300 people
- Sponsor
- Biocells (Beijing) Biotech Co.,Ltd
Abdominal Aortic Aneurysms
ViTAA Registry Pre- and Post-Operative Monitoring for Endovascular Aortic Aneurysm Repair and Serial Monitoring for AAA
This is a Prospective Registry study to collect imaging and clinical data both on patients with aortic aneurysm disease undergoing serial monitoring and on patients pre and post-endovascular repair, using ViTAA (The Sponsor)…
- Trial name
- NCT05004051
- Testing
- ViTAA Analysis
- Where
- 8 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- ViTAA Medical Solutions
Arterial Hypertension, Chronic Kidney Disease
PRospectIve ObseRvatIonal mulTicenter Study of Patients With Arterial hYpertension and CKD in the Population of Russia
This study is a multi-centre, non-interventional, observational, prospective study with retrospective analysis. The main purpose of the study is to describe the rate of CKD diagnosis in patients with AH and CKD markers.
- Trial name
- PRIORITY-CKD (NCT06372431)
- Where
- 30 sites in Russia
- Volunteers
- 9,914 people
- Sponsor
- AstraZeneca
Essential Hypertension
Safety and Pharmacokinetics Study of BCD101 in Healthy Volunteers
A randomized, double-blinded, single/multiple dosing, dose escalation Phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of BCD101 in healthy adult volunteers.
- Trial name
- NCT07282145
- Testing
- BCD101 Low Dose Liquid Formulation, BCD101 High Dose Liquid Formulation, BCD101 Low + High Dose Liquid Formulation
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Bichedam Co., Ltd.
Pulmonary Arterial Hypertension
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
This is a multi-center, open-label study for eligible participants who were actively participating in the BPS-314d-MR-PAH-302 double-blind study (NCT01908699) at the time the study was concluded.
- Trial name
- BEAT OLE (NCT03657095)
- Testing
- Esuberaprost
- Where
- 45 sites in United States, Israel
- Volunteers
- 112 people
- Sponsor
- Lung Biotechnology PBC
Stroke, Hemiparesis After Stroke
Prospective Real-World Evidence Study of the IpsiHand® System in Adult Stroke Survivors
This study focuses on monitoring real-world customers who have been prescribed the IpsiHand® as part of their rehabilitation post-stroke.
- Conditions
- Stroke, Hemiparesis After Stroke, Brain Computer Interface
- Trial name
- NCT07147881
- Testing
- IpsiHand
- Volunteers
- 100 people
- Sponsor
- Neurolutions, Inc.
Aortic Aneurysm, Thoracic, Aorta, Lesion
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1
The objective of this study is to determine whether the GORE® TAG® Thoracic Branch Endoprosthesis is safe and effective in treating lesions of the aortic arch and descending thoracic aorta.
- Trial name
- SSB 11-02 (NCT02777528)
- Testing
- GORE® TAG® Thoracic Branch Endoprosthesis, Revascularization Procedure
- Where
- 39 sites in United States, Japan
- Volunteers
- 79 people
- Sponsor
- W.L.Gore & Associates
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.